What confounds me is that Al Mann is one of the most prolific investors/entrepreneurs in the history of biotech. He has poured his own money into Mannkind/Afrezza hand over fist, so I am assuming he truly believes in the product. Perhaps in the old guard FDA, Afrezza gets the nod. In this environment, Tylenol would be a 50/50. Maybe the BV heavy hitters could shed some light.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.